Billings, Paul, MD, PhD

Chief Executive Officer and Director, Biological Dynamics Inc.

Chief Executive Officer and Director, Biological Dynamics Inc.

Board certified internist and clinical geneticist Dr. Paul R. Billings serves as Chief Medical Officer, a new position aimed at improving patient care through expanding the use of medically relevant genomic technologies in clinical settings. Dr. Billings brings extensive expertise and clinical experience in the areas of genomics and molecular medicine. Most recently, he served as Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital, the largest community hospital in the Silicon Valley. He currently serves as a member of the United States Department of Health and Human Services Secretary's Advisory Committee on Genetics, Health and Society, where he helps shape policy in the rapidly evolving field of genomic medicine. Dr. Billings has had a distinguished career as a physician and researcher. He has been a founder or chief executive officer of companies involved in genetic and diagnostic medicine, including GeneSage, Omicia and CELLective Dx Corporation. Previously, he was senior vice president for corporate development at Laboratory Corporation of America Holdings (LabCorp). He has held academic appointments at some of the most prestigious universities in the United States, including Harvard Medical School, Stanford School of Medicine and the University of California, Berkeley, and has served as a physician at a number of medical centers throughout the country, including the University of California, San Francisco. He is the author of nearly 200 publications and books on genomic medicine. Dr. Billings holds an M.D. from Harvard Medical School and a Ph.D. in immunology, also from Harvard University. Interview (published June 2022)
<a href="">Listen to an interview with Paul about Ion Sequencing and Genomic Medicine</a>


New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup